Member Info for bidnolid

It is the biggest insult for me as a shareholder to see such contempt by Suckling. That is 2 months on the spin he has failed in his PDMR and it's not like his days are particularly busy. I have absolutely no idea what value he adds, it is an absolute disgrace. I am also extremely angry they choose a date in the calendar when most people will be away on holiday so I will be unable to attend the AGM and give him a piece of my mind.

Ok so by that token you must also factor in that their evaluation could conclude that it's not worth pursuing. I've not invested in a drug reformulation co before so encouraging that the second attempt has a much better chance. Do you have any examples of drugs that got through at the second attempt? Would be interesting to look into them.

Chartist..well, the target that would have made it a viable drug within the context of their patent application I suppose. The first trial was a fail as hughwilson has now acknowledged, the second will hopefully be more successful although I don't think hope counts as an investment strategy

Err what? I'm not calling it a write off I'm just talking about the first trial. You just said that the RNS stated the trial failed to meet its target.. ergo it failed!

Did the RNS say it was a success then? NO. So what is the opposite of success...

Kind of pointless trying to shout facts at me when it spells out in the RNS it didn't work out. Yes it might be a temporary failure and hopefully salvageable, but a failure all the same.

I think it's another Marvel sequel ..

https://www.nuventra.com/services/pharmacokinetics-pharmacodynamics/

Hang on a minute hughwilson..I don't think you're in the position of chat board police considering you were on the 'rampy' side of things in the run up to July 9. All holders want the tweak to be nice and straightforward but this RNS was not reporting a success - "it is clear from the preliminary PK data that the current formulation has not met the key target endpoints of the trial"

Success
noun
the accomplishment of an aim or purpose.
antonyms: failure

As pettycash said in his post at the weekend, it's not good enough to simply pigeonhole someone as a deramper
... "especially when used in place of solid arguments".

Sorry, old post

https://twitter.com/BraveBisonIO/status/1025307237286391808

Miton, Lombard, Ennismore, Livingbridge .. has a very strong institutional base. The Cenkos note from last week was very positive and there appears to be an aggressive buy order working since midday today.

Top marks Petty..shame that was a Saturday post because it probably didn't get the audience it deserved. Even a bit of latin included! I think tribal is exactly the right way to describe it - shares are a monetary investment not an emotional one. The price fell because of deramping? Post hoc, ergo propter hoc.. :)

Are you serious, you think today's drop is down to a late night post from Chartist2? LOL I've heard some conspiracy theories in my time but that's a cracker!

And so Chartist isn't allowed to post that but you can chuck in fairly rampy stuff about N4 and nobody is allowed to say anything..hmmm

Steady on there hughwilson. We might not all agree with Chartist but there was a dose of sarcasm in his original post - we are all capable of cutting through the rubbish without having to attack the poor bloke. My personal opinion is that charting is a total waste of time on AIM stocks, but horses for courses and all that..

That's fair enough pettycash, can't grumble about your rationale. I would add there might be a short term shot in the arm from a research note, but that's not 'actual' news. Mazik - please don't misinterpret this as negative but broker notes only reiterate what the market already knows. If you look at the CLNR one (I don't hold), there was a temporary boost to the SP and a bit of a ripple of interest but ultimately it's only a piece of research put together by a small and very lightweight shop. We may well be in raptures about it here, but the rest of market won't give a hoot..the city has decamped to Cap d'Antibes until September!

http://www.allenbycapital.com/research/research-cluff-nat--resources_27_3955239325.pdf

8 minutes in - "telecoms are queuing up to work with us because this is a unique solution.." ermmm that's a pretty slow conversion rate Dave..!

Someone bought 97 quids worth. Must be an insti..

We have, just in the opposite direction..! Stating the obvious but all shares go through periods of being undervalued and overvalued - sadly it's only possible to see when they are from looking back with hindsight.. Let's hope we can look back on anything with a 7 or 8 handle as being the 'undervalued' period.. From an investor perspective these 15% spikes are a bit irrelevant (albeit fun) because they aren't based on any actual news..

Incredible really - watching that you can see why plenty of people invested in ENET. Over a year has passed and the world still hasn't adopted their solution.. hmmm. Maybe the world is just a bit too slow on the uptake..

Hi csn - sorry that sentence was to explain my own view. When I bought these shares I rather stupidly thought 'how difficult can it be?' to improve an old product like Viagra. If I was a totally new investor to N4 I'd probably take the view that things have changed since they listed - mainly because of that calamitous RNS from early July. It just made it sound like the whole trial was so wide of the mark it wasn't even worth waiting for the final results. But yes you are totally correct, there has been nothing from the company to corroborate that - their stance is still that they need to wait for the final results and then a decision can be made on what needs changing with the formulation.

This is from the finals released in June:

The balance sheet strength of the Company remains sound with substantial cash reserves in place to meet the expansion requirements of the business.

The net cash utilised in operating activities for the year is $437,249, however following the IPO, cash reserves have increased from $335,723 at the end of 2016 to $14,950,578 as of 31 December 2017. Short and long term borrowings and loans have been reduced from $786,672 to $7,522 while working capital management remains tightly controlled.

The directors are satisfied that the cash resources are more than sufficient to meet the long term plans of the Company.